Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
NCT ID: NCT03062176
Last Updated: 2019-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2017-04-03
2019-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-Cytokine Therapy for Hemodialysis InflammatION
NCT03141983
Everolimus on CKD Progression in ADPKD Patients
NCT01009957
Evolocumab In Advanced Chronic Kidney Disease Trial
NCT04510844
Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome
NCT03019653
A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)
NCT00683553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Treatment
Anakinra (Kineret)
Anakinra
Anakinra (Kineret)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anakinra
Anakinra (Kineret)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older
* Chronic heart failure
* Left ventricular ejection fraction less than 50%
* C-reactive protein greater than or equal to 2 mg/L
* Maintenance hemodialysis with a biocompatible membrane, acceptable dialysis adequacy (Kt/V \> 1.2), and receipt of a stable hemodialysis prescription for at least 4 weeks OR chronic kidney disease stage IV/V (estimated glomerular filtration rate \<30 mL/min/1.73m2)
Exclusion Criteria
* Need for urgent or emergent care
* Recent use of immunosuppressant, anti-inflammatory therapies or active rheumatologic disease
* Allergy to rubber, latex, Escherichia coli or anakinra
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Virginia Commonwealth University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin W Van Tassell, PharmD
Role: PRINCIPAL_INVESTIGATOR
Virginia Commonwealth University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM20007618
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.